SetDB2: A Potential Drug Target and Biomarker for Lysine N-Methyltransferase 1F

Target Name: SETDB2

NCBI ID: G83852

SETDB2

SetDB2: A Potential Drug Target and Biomarker for Lysine N-Methyltransferase 1F

Introduction

Lysine N-methyltransferase 1F (SETDB2) is an enzyme that plays a crucial role in the regulation of gene expression and DNA methylation. SetDB2 is highly expressed in various tissues and cell types, including brain, muscle, and immune cells. It is known to be involved in the transfer of methyl groups from the promoter region to the methylated gene. The de novo methylation of lysine residues has been reported to play a role in the regulation of gene expression and the development of various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases.

Recent studies have identified potential drug targets for SETDB2 based on its involvement in various cellular processes. One of the most promising targets is the inhibition of SETDB2, which could lead to the demethylation of lysine residues and the activation of gene expression.

The Druggability of SETDB2

SETDB2 is a protein that can be targeted by small molecules, such as inhibitors, dyes, or antibodies. In recent years, several studies have investigated the potential drug targets for SETDB2 and identified several compounds that are known to interact with the protein.

One of the most promising compounds is N-Acetyl-L-Tyrosine (NAT), which is an inhibitor of the enzyme tyrosine aminotransferase (TAT). NAT has been shown to inhibit the activity of SETDB2 and has been shown to have potential as a drug against various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases.

Another compound that has been shown to interact with SETDB2 is 2-[(2-methylpropyl) amino]-2-naphthalene diazonium ion (SN502), which is a inhibitor of the enzyme cyclic ADP-ribose synthase (CARDS). CARDS is a key enzyme in the production of cyclic ADP-ribose, which is a potent free radical inducer and has been linked to the development of various diseases, including cancer.

In addition to these inhibitors, several other compounds have also been shown to interact with SETDB2. These include inhibitors of the enzyme heat shock protein (HSP) 16.0, which is involved in the regulation of cellular stress responses, and inhibitors of the enzyme heat shock protein (HSP) 70, which is involved in the regulation of protein folding and degradation.

The efficacy of these drugs may depend on their ability to interact with SETDB2 and the specific context in which the drug is used. Therefore, further studies are needed to determine the efficacy and safety of these drugs as potential drug targets for SETDB2.

Conclusion

SETDB2 is a protein that plays a crucial role in the regulation of gene expression and DNA methylation. The de novo methylation of lysine residues has been reported to play a role in the regulation of various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. In recent years, several studies have identified potential drug targets for SETDB2 based on its involvement in various cellular processes. The most promising compounds identified so far include N-Acetyl-L-Tyrosine, 2-[(2-methylpropyl) amino]-2 -naphthalene diazonium ion, and heat shock protein (HSP) 16.0 and HSP 70. Further studies are needed to determine the efficacy and safety of these drugs as potential drug targets for SETDB2.

Protein Name: SET Domain Bifurcated Histone Lysine Methyltransferase 2

Functions: Histone methyltransferase involved in left-right axis specification in early development and mitosis. Specifically trimethylates 'Lys-9' of histone H3 (H3K9me3). H3K9me3 is a specific tag for epigenetic transcriptional repression that recruits HP1 (CBX1, CBX3 and/or CBX5) proteins to methylated histones. Contributes to H3K9me3 in both the interspersed repetitive elements and centromere-associated repeats. Plays a role in chromosome condensation and segregation during mitosis

The "SETDB2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SETDB2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets